Brokerages Set Xencor, Inc. (NASDAQ:XNCR) Target Price at $24.88

Shares of Xencor, Inc. (NASDAQ:XNCR) have earned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $24.8750.

Several equities research analysts have weighed in on XNCR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Monday, December 29th. Royal Bank Of Canada upped their price objective on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Barclays increased their target price on shares of Xencor from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Cantor Fitzgerald boosted their price target on shares of Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Finally, Wedbush reiterated an “outperform” rating and set a $26.00 price objective on shares of Xencor in a research note on Thursday, November 6th.

Insiders Place Their Bets

In related news, VP John R. Desjarlais sold 73,367 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the sale, the vice president directly owned 236,574 shares in the company, valued at $3,718,943.28. This represents a 23.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Bassil I. Dahiyat sold 114,377 shares of Xencor stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $15.71, for a total value of $1,796,862.67. Following the completion of the transaction, the chief executive officer owned 466,635 shares in the company, valued at $7,330,835.85. This trade represents a 19.69% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.76% of the stock is owned by corporate insiders.

Institutional Trading of Xencor

Institutional investors have recently modified their holdings of the company. Walleye Capital LLC purchased a new position in shares of Xencor in the second quarter worth $1,955,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Xencor by 153.2% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 29,371 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 17,773 shares during the period. Squarepoint Ops LLC raised its stake in Xencor by 3,150.0% in the 2nd quarter. Squarepoint Ops LLC now owns 363,153 shares of the biopharmaceutical company’s stock worth $2,854,000 after acquiring an additional 351,979 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its position in Xencor by 93.0% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 95,745 shares of the biopharmaceutical company’s stock worth $753,000 after acquiring an additional 46,140 shares during the period. Finally, Panagora Asset Management Inc. grew its stake in Xencor by 68.4% during the 2nd quarter. Panagora Asset Management Inc. now owns 488,892 shares of the biopharmaceutical company’s stock valued at $3,843,000 after purchasing an additional 198,564 shares during the last quarter.

Xencor Price Performance

Xencor stock opened at $13.00 on Monday. The stock has a market cap of $928.33 million, a price-to-earnings ratio of -7.34 and a beta of 0.97. The firm has a 50-day moving average of $15.53 and a two-hundred day moving average of $12.14. Xencor has a 1 year low of $6.92 and a 1 year high of $21.00.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.64. Xencor had a negative net margin of 87.14% and a negative return on equity of 20.44%. The firm had revenue of $21.00 million during the quarter, compared to the consensus estimate of $29.73 million. During the same quarter in the previous year, the firm posted ($0.71) earnings per share. The company’s revenue was up 18.0% on a year-over-year basis. Research analysts expect that Xencor will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.